49 results on '"Yamamoto, Tatsuyoshi"'
Search Results
2. Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study
3. A global phase III study of pabinafusp alfa (JR-141) for neuronopathic mucopolysaccharidosis type II: Updated study design
4. Caregiver Perspectives on Patients with Mucopolysaccharidosis II Treated with Pabinafusp Alfa: Results of Qualitative Interviews in Japan
5. Integrated long-term efficacy and safety data on enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis type II (MPS II): Updated clinical data from Japan and Brazil
6. Long-term neurodevelopmental changes in subjects with MPS II following long-term treatment with pabinafusp alfa: An integrated analysis from pre- and post-approval clinical trials in Brazil and Japan
7. Real-world data of enzyme replacement therapy with pabinafusp alfa for neuronopathic MPS-II: Updated clinical data from Japan
8. Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis
9. Long term efficacy and safety of pabinafusp-alfa (JR-141) in Hunter syndrome (MPS-II): 104-week data from the clinical trials in Japan and Brazil
10. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
11. Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report
12. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil
13. Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II : an integrated analysis of preclinical and clinical data
14. Therapy for mucopolysaccharidosis type II with an intravenous blood-brain barrier-crossing enzyme (JR-141): Phase III global clinical trial design
15. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II
16. Exploration of the efficacy of pabinafusp-alfa (JR-141) on neurocognitive development in Hunter syndrome (MPS II): 52-week data from clinical trials in Japan and Brazil
17. Drug delivery across the blood-brain barrier and resultant reduction of heparan sulfate in the cerebrospinal fluid in the patients with Hunter syndrome (MPS II): An integrated analysis of 25-week Japanese and Brazilian data on pabinafusp alfa (JR-141)
18. Intercept-PCR, an improvement for elevating performance to find a new member of a certain gene family
19. Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studies
20. Endoscopic Rives-Stoppa Procedure for Incisional Ventral Hernia after Subtotal Stomach Preserving Pancreaticoduodenectomy
21. Therapy for mucopolysaccharidosis type II with an intravenous blood-brain barrier-crossing enzyme (JR-141): 26-week results from a phase 3 study in Japan suggesting significant efficacy against central nervous system and systemic symptoms
22. Results from a phase 2 trial of a blood-brain barrier penetrating enzyme (JR-141) in patients with MPS II in Brazil
23. Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report.
24. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial
25. Peritoneal Serous Papillary Adenocarcinoma at the Wound Site of Appendectomy
26. Efficacy and safety of JR-051, a biosimilar of agalsidase beta, in patients with Fabry disease; results of a multicenter, open-label phase 3 study in Japan
27. Novel blood-brain barrier delivery system to treat CNS in MPS II: First clinical trial of anti-transferrin receptor antibody fused enzyme therapy
28. Intravenously Administered Iduronate-2-Sulfatase Fused with Anti-Human Transferrin Receptor Antibody (Jr-141) Crosses the Blood-Brain Barrier to Address Central Nervous System Disorders in Hunter Syndrome: A Randomised, Open-Label, Phase 1/2 Trial
29. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial
30. Treatment of a giant inguinal hernia using transabdominal pre-peritoneal repair
31. Fibrinolytic Treatment of Acute Digital Artery Occlusion in Upper Extremities: a case report
32. Treatment of a Giant Inguinal Hernia Using Trans-abdominal Preperitoneal Repair
33. A Comprehensive Expression Analysis of Mucins in Appendiceal Carcinoma in a Multicenter Study: MUC3 Is a Novel Prognostic Factor
34. HEPATIC PORTAL VENOUS GAS ASSOCIATED WITH BOWEL OBSTRUCTION DUE TO OVARIAN CYST TORSION
35. SIRPα1 and SIRPα2: Their role as tumor suppressors in breast carcinoma cells
36. A CASE OF THE STRANGULATED ILEUS INDUCED BY INTRAUTERINE DEVICE
37. Novel Development Rescuing Factors (DRFs) Secreted by the Developing Dictyostelium Cells, That are Involved in the Restoration of a Mutant Lacking MAP-kinase ERK2
38. Profiling of gene expression associated with hepatolithiasis by complementary DNA expression array
39. Expression of p73 gene, cell proliferation and apoptosis in breast cancer: Immunohistochemical and clinicopathological study
40. p73 is highly expressed in myoepithelial cells and in carcinomas with metaplasia
41. Molecular cloning and characterization of a novel human gene (NESCA) which encodes a putative adapter protein containing SH3
42. A CASE OF NON-OCCLUSIVE MESENTERIC ISCHEMIA ASSOCIATED WITH PORTAL VENOUS GAS
43. Thyroglossal duct remnant penetrating the hyoid bone—A case report
44. A CASE OF SECONDARY SCLEROSING CHOLANGITIS PRESENTED DIFFICULTIES IN DIFFERENTIATION FROM HILAR CHOLANGIOCARCINOMA
45. A Case of Breast Angiosarcoma. An Application of Ki-67 Cell Proliferation Index for the Diagnosis of Very Well Differentiated Angiosarcoma.
46. ACUTE ABDOMEN IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD)-REPORT OF TWO CASES-
47. A CASE OF SMALL BOWEL OBSTRUCTION FOLLOWING LAPAROSCOPIC HERNIA REPAIR
48. Combination Therapy with Endoscopic Papillotomy and Laparoscopic Cholecystectomy for Cholecystochole-docholithiasis.
49. Efficacy and safety of GH treatment in Japanese children with short stature due to SHOX deficiency: a randomized phase 3 study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.